Abstract:
Compounds having the structure of general formula (I) or a pharmaceutically acceptable salt thereof have activity as inhibitors of cyclooxygenase and 5-lipoxygenase, reduce the biosynthesis of leukotrienes B4, C4, D4, and E4 and cyclooxygenase products such as prostaglandins and thromboxane and are useful in the treatment of inflammatory and allergic disease states. The compounds have the structure indicated above wherein A is selected from (a) optionally susbtituted carbocyclic aryl, (b) optionally substituted furyl, (c) optionally substituted benzo[b]furyl, (d) optionally substituted thienyl, (e) optionally substituted pyridyloxy, (f) optionally substituted pyridylalkyl, (g) optionally substituted benzo[b]thienyl, (h) optionally substituted pyridyl, (i) optionally substituted quinolyl, and (j) optionally substituted indolyl; X is selected from (a) optionally susbtituted alkyl, (b) optionally substituted alkenyl, and (c) optionally substituted alkynyl; R and R are independently selected from hydrogen, hydroxy, and alkyl; and Z is a residue of a non-steroidal anti-inflammatory drug of the general formula Z-COOH.
Abstract translation:具有通式(I)结构的化合物或其药学上可接受的盐具有作为环加氧酶和5-脂氧合酶抑制剂的活性,降低了白三烯B4,C4,D4和E4以及环氧合酶产物如前列腺素和血栓素的生物合成, 可用于治疗炎症和过敏性疾病状态。 化合物具有上述结构,其中A选自(a)任选取代的碳环芳基,(b)任选取代的呋喃基,(c)任选取代的苯并[b]呋喃基,(d)任选取代的噻吩基,(e) 吡啶基氧基,(f)任选取代的吡啶基烷基,(g)任选取代的苯并[b]噻吩基,(h)任选取代的吡啶基,(i)任选取代的喹啉基,和(j)任选取代的吲哚基; X选自(a)任选的取代的烷基,(b)任选取代的烯基,和(c)任选取代的炔基; R 1和R 2独立地选自氢,羟基和烷基; Z为通式Z-COOH的非甾体抗炎药物的残基。
Abstract:
Compounds of structure (I), wherein W is selected from (a), and (b), where Q is oxygen or sulfur, R and R are hydrogen or alkyl, or R and R , together with the nitrogen atoms to which they are attached, define a radical of formula (II) or (III), R is selected from hydrogen, alkyl, haloalkyl, optionally substituted phenyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, (alkoxycarbonyl)alkyl, and (alkylaminocarbonyl)alkyl; Z is -CH2-, oxygen, sulfur, or -NR where R is hydrogen or alkyl, L and L are selected from a valence bond, alkylene, propenylene, and propynylene, R , R , R , and R are independently selected from alkyl, haloalkyl, halogen, cyano, amino, alkoxycarbonyl, and dialkylaminocarbonyl, Y is selected from oxygen, -NR , where R is hydrogen or alkyl, and (c), where n = 0, 1, or 2, and R is alkyl, inhibit the biosynthesis of leukotrienes. These compounds are useful in the treatment or amelioration of allergic and inflammatory disease states.
Abstract:
Compounds of formula (I) Z-Ar 1 -Ar 2 wherein Z is a diazabicyclic amine, Ar 1 is a 5- or 6-membered aromatic ring, and Ar 2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.
Abstract:
Compounds of the formula (I), wherein A is selected from NR1R2 and N(OR6)R2; and B and C are chloro when A is N(OR6)R2 or are independently selected from NHR3 and NR4R5 where R1, R2, R3, R4 and R5 are independently selected from the group consisting of alkyl, cycloalkyl and alkylaryl each of which may be unsubstituted or substituted with one or more substituents selected from the group consisting of hydroxy, OR, NRR, OCOR, OCONRR, NRCOR and NRCONRR where R is selected from the group consisting of hydrogen, alkyl, aryl, alkylaryl, alkoxy and hydroxy or R1 and R2 or R4 and R5 together can form a heteroaryl group and R6 is a member selected from the group consisting of hydrogen, alkyl, alkylaryl and trialkylsilyl; and the pharmaceutically acceptable salts thereof. These compounds are useful as inhibitors of lipoxygenase enzymes.
Abstract:
Compounds of formula (I), pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals (nicotinic acetylcholine receptor ligands).
Abstract:
The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important 'housekeeping' enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
Abstract:
L'invention concerne des composés ayant la formule (I) dans laquelle p et q sont égaux à zéro ou un, mais sont différents l'un de l'autre, M est un cation pharmaceutiquement acceptable ou un groupe clivable par le métabolisme, B est une liaison de valence ou un groupe alkylène linéaire ou ramifié, R est alkyle, cycloalkyle ou -NR1R2, où R1 et R2 sont hydrogène, alkyle, cycloalkyle ou alcanoyle, et A est aryle, furyle, benzo[b]furyle, thiényle ou benzo[b]thiényle carbocyclique substitué ou non; ces composés sont de puissants inhibiteurs des enzymes de lipoxygénase et par conséquent ils inhibent la biosynthèse des leukotriènes. Les composés de cette invention sont utiles pour traiter ou pour améliorer les états pathologiques allergiques et inflammatoires.
Abstract:
Compounds of the structure (I) where p and q are zero or one, but cannot both be the same, M is a pharmaceutically acceptable cation or a metabolically cleavable group, B is a valence bond or a straight or branched alkylene group, R is alkyl, cycloalkyl or -NR1R2, where R?1 and R2¿ are hydrogen, alkyl, cycloalkyl or alkanoyl, and A is optionally substituted carbocyclic aryl, furyl, benzol[b]furyl, thienyl, or benzol[b]thienyl are potent inhibitors of lipoxygenase enzymes and thus inhibit the biosynthesis of leukotrienes. These compounds are useful in the treatment or amelioration of allergic and inflammatory disease states.
Abstract:
The invention relates to compounds having activity to inhibit lipoxygenase enzyme activity, to pharmaceutical compositions comprising these compounds, and to a medical method of treating. More particularly, this invention concerns certain substituted arylalkynyl- and ((heteroaryl)alkynyl)-N-hydroxy-ureas which inhibit leukotriene biosynthesis, to pharmaceutical compositions of these compounds and to a method of inhibiting leukotriene biosynthesis.
Abstract:
A series of 3-pyrrolidinyloxy-3'-pyridyl ether compounds, a method for selectively controlling neurotransmitter release in mammals using these compounds, and pharmaceutical compositions including these compounds. Preferred compounds are 3-pyrrolidinylmethoxy-3'-(5'-and/or 6'-substituted) pyridyl ethers.